公开(公告)号：US12129299B2

公开(公告)日：2024-10-29

申请号：US16967079

申请日：2019-01-29

Applicant: ONCOC4, INC. ,  University of Maryland, Baltimore

Inventor： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K16/2827 ,  C07K2317/565 ,  C07K2317/71

Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US12128102B2

公开(公告)日：2024-10-29

申请号：US18357013

申请日：2023-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Patrick Baeuerle ,  Robert B. DuBridge ,  Holger Wesche ,  Luke Evnin ,  Jeanmarie Guenot ,  Anand Panchal ,  Maia Vinogradova

IPC: G01N31/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  G01N33/53 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/50

Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

公开(公告)号：US20240352139A1

公开(公告)日：2024-10-24

申请号：US18036144

申请日：2021-11-11

Applicant: BEIJING IMMUNOAH PHARMATECH CO., LTD.

Inventor： Xin GAO ,  Niliang QIAN ,  Xiujie PAN ,  Guili XU ,  Yujie LIU ,  Hongjie LI ,  Cuima YANG ,  Qinzhi XU ,  Xiaoqian DOU ,  Yunhui LIU ,  Zhenjun YU ,  Guijun BAI

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3069 ,  C07K16/3084 ,  C07K16/3092 ,  C07K2317/21 ,  C07K2317/31

Abstract: The present application provides a fusion protein, containing: an anti-CD137 antibody capable of specifically binding to a CD137 molecule or an antigen binding fragment thereof; an anti-CD3 antibody capable of specifically binding to a CD3 molecule or an antigen binding fragment thereof; and a first peptide linker and a second peptide linker. The present application also provides a nucleic acid encoding the fusion protein, an expression vector containing the nucleic acid, a host cell containing the nucleic acid or the expression vector, a method for preparing the fusion protein, a pharmaceutical composition containing the fusion protein, and a use of the fusion protein.

公开(公告)号：US20240350589A1

公开(公告)日：2024-10-24

申请号：US18683180

申请日：2022-08-16

Applicant: Cytune Pharma

Inventor： Lenka Kyrych Sadilkova ,  Ulrich Moebius ,  David Béchard ,  Irena Adkins

IPC: A61K38/20 ,  A61K9/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K38/2086 ,  A61K9/0019 ,  A61K38/1793 ,  A61K45/06 ,  A61K47/6855 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: The invention relates to an interleukin-2/interleukin-receptor βγ(IL-2/IL-15Rβγ) agonist for use in treating cancer in a patient, wherein said IL-2/IL-15Rβγ agonist is administered in combination with a cytotoxic compound capable of inducing immunogenic cell death (TCD) or in combination with an application of a modality capable of inducing TCD.

公开(公告)号：US20240343809A1

公开(公告)日：2024-10-17

申请号：US18580389

申请日：2022-07-19

Applicant: EXCELMAB INC.

Inventor： Wenjun ZHANG ,  Min LIU ,  Wenwu TIAN ,  Feng LI ,  Yanan HUA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56

Abstract: A B7-H3 antibody and a use thereof are provided. The heavy chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 6-8, and the light chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 14-16. The B7-H3 antibody can bind to a B7-H3 antigen and/or cells expressing the B7-H3 antigen. A B7-H3×CD3 bispecific antibody is constructed by using the B7-H3 antibody.

公开(公告)号：US20240343808A1

公开(公告)日：2024-10-17

申请号：US18392954

申请日：2023-12-21

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Gordon James Freeman ,  Arlene Helen Sharpe ,  Gerhard Johann Frey ,  Hwai Wen Chang ,  Jennifer Marie Mataraza ,  Glenn Dranoff

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：US20240336702A1

公开(公告)日：2024-10-10

申请号：US18743295

申请日：2024-06-14

Applicant: AB STUDIO INC.

Inventor： Yue Liu ,  Wenyan Cai ,  Jiadong Shi

IPC: C07K16/46 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2896 ,  A61K2039/505

Abstract: This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.

公开(公告)号：US20240335538A1

公开(公告)日：2024-10-10

申请号：US18290668

申请日：2022-07-21

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Tae-Don KIM ,  Sooyun LEE

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783

CPC classification number: A61K39/464404 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4615 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464419 ,  A61K39/464429 ,  A61K39/464466 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/303 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

Abstract: The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

公开(公告)号：US12110332B2

公开(公告)日：2024-10-08

申请号：US16765008

申请日：2017-11-20

Applicant: Taizhou Mabtech Pharmaceutical Co., Ltd.

Inventor： Yajun Guo

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/705

CPC classification number: C07K16/2827 ,  A61P35/00 ,  A61P37/02 ,  C07K14/70503 ,  C07K16/2896 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2319/70

Abstract: A bifunctional fusion protein targeting CD47 and PD-L1, which belongs to the field of biomedicine and solves the problems that anti-PD-1/PD-L1 treatment has poor effect on low immunogenic tumors and anti-CD47 treatment has poor targeting properties. The fusion protein consists of a CD47-binding moiety and a PD-L1-binding moiety linked by means of a disulfide bond, can block both the binding of CD47 to SIRPa and the binding of PD-L1 to PD-1, not only activating macrophage phagocytosis of tumor cells and promoting antigen presentation in innate immunity, but also promoting tumor-specific T cell activation in acquired immunity, and has lower hematological toxicity. The fusion protein has better anti-tumor efficacy and hematological safety than anti-PD-L1 or anti-CD47 therapy alone, and animals from which a tumor has disappeared after the treatment of the fusion protein produce immunity against re-inoculation of the same tumor cell.

公开(公告)号：US20240327506A1

公开(公告)日：2024-10-03

申请号：US18620778

申请日：2024-03-28

Applicant: MaineHealth

Inventor： Xianghua Han ,  Jennifer M. Caron ,  Peter C. Brooks

IPC: C07K16/18 ,  A61K35/17 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K35/17 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2848

Abstract: The present invention provides compositions and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases by enhancing adoptive cell therapy. In some embodiments, the methods provided herein increase T-cell infiltration into a tumor.